Study of CD38 and CD56 in Chronic Myeloid Leukemia
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: cd 38 and cd 56.
- Who it may be relevant to
- Registry conditions: Chronic Myeloid Leukemia (CML). Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Aberrant Expression of CD56 on CD38 Positive Neutrophils as a Novel Diagnostic Tool in Chronic Myeloid Leukemia
Overview
Chronic myeloid leukemia is a myelo-proliferative neoplasm characterized by abnormal proliferation of myeloid cells. There is an accumulation of mature granulocytes in the blood and bone marrow. The aim of the study is to study expression of CD38 and CD56 in patients with Chronic myeloid leukemia.
Interventions
- Diagnostic test cd 38 and cd 56
prescence of high percentage of cd38 and cd 56
Primary outcome measures
- an increased change in cd 38 and cd 56 in chronic leukemic patients [Time frame: 6 months]
Eligibility criteria
Inclusion criteria
- patients with chronic myeloid leukemia
Exclusion criteria
- other hematological diseases
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Case-control
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07740603 · Soh-Med-26-6-9MS